Wpływ limfocytów T i mieloidalnych komórek supresorowych na hamowanie odpowiedzi antynowotworowej organizmu

• Autorzy: Mucha J. , Motyl T. , Krol M.

Warianty tytułu

EN

Influence of lymphocytes T and myeloid-derived suppressor cells on inhibition of antitumor response

• Języki publikacji: PL

Abstrakty

EN

For many years research on tumour development focused exclusively on the functions of cancer cells. Less attention was paid to tumour-associated cells, which form the tumour microenvironment. Nowadays we know that inflammatory infiltration cells associated with tumour proliferation may have a pro-tumour or an anti-tumour effect. Current studies are focused on interaction (cross-talk) between cells in the tumour microenvironment. Myeloid suppressor cells (MDSCs) and lymphocytes T are special groups of cells associated with tumour. Interaction between cancer cells, MDSCs and lymphocytes T leads to the development of an immunosuppression network that prevents effective combat against cancer cells and creates conditions favourable for tumour progression, migration and metastasis. The understanding of the crosstalk between cancer cells and immune cells has become the main task of scientists and oncologists.

Słowa kluczowe

PL

psy; nowotwory; immunosupresja; rozwoj choroby; procesy nowotworzenia; limfocyty T; subpopulacje limfocytow; mieloidalne komorki supresyjne

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2016
• Tom: 72
• Numer: 12
• Opis fizyczny: s.735-739,rys.,bibliogr.

Twórcy

autor

Mucha J.

• Katedra Nauk Fizjologicznych, Wydział Medycyny Weterynaryjnej, Szkoła Główna Gospodarstwa Wiejskiego w Warszawie, ul. Nowoursynowska 159, 02-776 Warszawa

autor

Motyl T.

• Katedra Nauk Fizjologicznych, Wydział Medycyny Weterynaryjnej, Szkoła Główna Gospodarstwa Wiejskiego w Warszawie, ul. Nowoursynowska 159, 02-776 Warszawa

autor

Krol M.

• Katedra Nauk Fizjologicznych, Wydział Medycyny Weterynaryjnej, Szkoła Główna Gospodarstwa Wiejskiego w Warszawie, ul. Nowoursynowska 159, 02-776 Warszawa

Bibliografia

• Aggarwal B. B., Shishodia S., Sandur S. K., Pandey M. K., Sethi G.: Inflammation and cancer: how hot is the link? Biochem. Pharmacol. 2006, 72, 1605-1621.
• Balkwill F., Mantovani A.: Cancer and inflammation: implications for pharmacology and therapeutics. Clin. Pharmacol. Therap. 2010, 87, 401-406.
• Bartoli M., Platt D., Lemtalasi T., Gu X., Brooks S. E., Marrero M. B., Caldwell R. B.: VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 2003, 17, 1562-1564.
• Boehmer H. von, Daniel C.: Therapeutic opportunities for manipulating T (Reg) cells in autoimmunity and cancer. Nature Rev. Drug Discov. 2013, 12, 51-63.
• Campbell M. J., Scott J., Maecker H. T., Park J. W., Esserman L. J.: Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res. 2005, 91, 163-171.
• Curigliano G.: Immunity and autoimmunity: revising the concepts of response to breast cancer. Breast 2011, 20, supplement 3, S71-S74.
• DeNardo D. G., Coussens L. M.: Inflammation and breast cancer. Balancingimmune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007, 9, artykuł 212.
• Dunn G. P., Old L. J., Schreiber R. D.: The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21, 137-148.
• Finn O. J.: Molecular origins of cancer: cancer immunology. New England J. Med. 2008, 358, 2704-2715.
• Fukumura D., Jain R. K.: Tumor Microenvironment Abnormalities: Causes, Consequences, and Strategies to Normalize. J. Cell Biochem. 2007, 101, 937-949.
• Gabrilovich D. I., Nagaraj S.: Myeloid-derived suppressor cells as regulators of the immune system. Nature Rev. Immunol. 2009, 9, 162-174.
• Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoué F., Bruneval P., Cugnenc P.-H., Trajanoski Z., Fridman W.-H., Pagès F.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960-1964.
• Goulart M. R., Pluhar G. E., Ohlfest J. R.: Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer. PLoS One. 2012;7(3):e33274. doi: 10.1371/journal.pone.0033274. Epub 2012 Mar 13.
• Hadrup S. R., Brćndstrup O., Jacobsen G. K., Per thor Straten: Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells. Internat. J. Cancer 2006, 119, 831-838.
• Karin M.: Nuclear factor-kappa B in cancer development and progression. Nature 2006, 441, 431-436.
• Kitamura T, Pollard J. W.: Therapeutic potential of chemokine signal inhibition for metastatic breast cancer. Pharmacol. Res. 2015, 100, 266-270. doi: 10.1016/j.phrs.2015.08.004.
• Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., Niu G., Kay H., Mule J., Kerr W. G., Jove R., Pardoll D., Yo H.: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 2005, 11, 1314-1321.
• Król M., Pawłowski K. M., Majchrzak K., Dolka I., Abramowicz A., Szyszko K., Motyl T.: Density of tumor-associated macrophages (TAMs) and expression of their growth factor receptor MCSF-R and CD14 in canine mammary adenocarcinomas of various grade of malignancy and metastasis. Polish J. Vet. Sci. 2011, 14, 3-10.
• Kujawski M., Kortylewski M., Lee H., Herrmann A., Kay H., Yu H.: Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 2010, 118, 3367-3377.
• Kuroda H., Tamaru J., Sakamoto G., Ohnisi K., Itoyama S.: Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch. 2005, 446, 10-14.
• Larusso G., Rüegg C.: The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol. 2008, 130, 1091-1103.
• Lee H. E., Chae S. W., Lee Y. J., Kim M. A., Lee H. S., Kim W. H.: Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br. J. Cancer 2008, 99, 1704-1711.
• Łuczyński W., Krawczuk-Rybak M., Stasiak-Barmuta A.: Myeloid-derived suppressor cells – the new mechanizm of immunosuppression in cancer. Post. Hig. Med. Dosw. 2008, 62, 18-22.
• Macchetti A. H., Marana H. R., Silva J. S., de Andrade J. M., Ribeiro-Silva A., Bighetti S.: Tumor-infiltrating CD4+T lymphocytes in early breast cancer reflect lymph node involvement. Clinics 2006, 61, 203-208.
• Mantovani A., Allavena P., Sica A., Balkwill F.: Cancer-related inflammation. Nature 2008, 454, 436-444. doi: 10.1038/nature07205.
• Marigo I., Dolcetti L., Serafini P., Zanovello P., Bronte V.: Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 2008, 222, 162-179.
• Mittal D., Gubin M. M., Schreiber R. D., Smyth M. J.: New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr. Opin. Immunol. 2014, 27, 16-25. doi: 10.1016/j.coi.2014.01.004.
• Morrison W. B.: Inflammation and cancer: a comparative view. J. Vet. Int. Med. 2012, 26, 18-31.
• Mucha J., Majchrzak K., Taciak B., Hellmén E., Król M.: MDSCs mediate angiogenesis and predispose canine mammary tumor cells for metastasis via IL-28/IL-28RA (IFN-λ) signaling. PLoS One 2014, 9(7), e103249. doi: 10.1371/journal.pone.0103249.
• Mucha J., Rybicka A., Dolka I., Szymańska J., Manuali E., Parzeniecka-Jaworska M., Kluciński W., Król M.: Immunosuppression in dogs during mammary cancer development. Vet. Path. 2016 doi: 10.1177/0300985816634808.
• Niu G., Wright K. L., Huang M., Song L., Haura E., Turkson J., Zhang S., Wang T., Sinibaldi D., Coppola D., Heller R., Ellis L. M., Karras J., Bromberg J., Pardoll D., Jove R., Yu J.: Constitutive Stat3 activity up-regulated VEGF expression and tumor angiogenesis. Oncogene 2002, 21, 2000-2008.
• Pagès F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., Meatchi T., Bruneval P., Cugnenc P., Trajanoski Z., Fridman W., Galon J.: Effector memory T cells, early metastasis, and survival in colorectal cancer. New England J. Med. 2005, 353, 2654-2666.
• Pan P. Y., Wang G. X., Yin B., Ozao J., Ku T., Divino C. M., Chen S. H.: Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008, 111, 219-228.
• Panapoulous A. D., Zhang L., Snow J. W., Jones D. M., Smith A. M., El Kasmi K. C., Liu F., Goldsmith M. A., Link D. C., Murray P. J., Watowich S. S.: STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. Blood 2006, 108, 3682-3690.
• Piersma S. J., Jordanova E. S., van Poelgeest M. I. E., Kwappenberg K. M., van der Hulst J. M., Drijfhout J. W., Melief C. J., Kenter G. G., Fleuren G. J., Offringa R., van der Burg S. H.: High number of intraepithelialCD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007, 67, 354-361.
• Piras F., Colombari R., Minerba L. Murtas D., Floris C., Maxia C., Corbu A., Perra M. T., Sirigu P.: The predictive value of CD8, CD4, CD68 and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005, 104, 1246-1254.
• Sakaguchi S., Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T.: Regulatory T cells: how do they suppress immune responses? Internat. Immunol. 2009, 21, 1105-1111.
• Schmid M. C., Varner J. A.: Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J. Oncol. 2010, doi:10.1155/2010/201026.
• Sethi G., Shanmugam M. K., Ramachandran L., Kumar A. P., Tergaonkar V.: Multifaceted link between cancer and inflammation. Biosci. Rep. 2012, 32, 1-15.
• Sharma P., Shen Y., Wen S., Yamada S., Jungbluth A. A., Gnjatic S., Bajorin D. F., Reuter V. E., Herr H., Old L. J., Sato E.: CD8 tumor-infiltrating lymphocytes are predictive of survival inmuscle-invasive urothelial carcinoma. Proc. Nat. Acad. Sci. USA 2007, 104, 3967-3972.
• Sherger M., Kisseberth W., London C., Olivo-Marston S., Papenfuss T. L.: Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs. BMC Vet. Res. 2012, 31, 8, 209. doi: 10.1186/1746-6148-8-209.
• Sheu B., Kuo W., Chen R., Huang S., Chang K., Chow S.: Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer. Breast 2008, 17, 604-610.
• Szala S.: Komórki mikrośrodowiska nowotworowego: cel terapii przeciwnowotworowej. Nowotwory. J. of Oncol. 2007, 57, 633-645.
• Tanchot C., Terme M., Pere H., Tran T., Benhamouda N., Strioga M., Banissi C., Galluzzi L., Kroemer G., Tartour E.: Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron. 2013, 6, 147-157.
• Taylor R. C., Patel A., Panageas K. S., Busam K. J., Brady M. S.: Tumorinfiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J. Clin. Oncol. 2007, 25, 869-875.
• Toḿsová M., Melichar B., Sedláková I., Steiner I.: Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol. Oncol. 2008, 108, 415-420.
• Vakkila J., Lotze M. T.: Inflammation and necrosis promote tumour growth. Nat. Rev. Immunol. 2004, 4, 641-648.
• Yakirevich E., Lefel O., Sova Y., Savage C. O. S.: Fractalkine expression in human renal inflammation. J. Path. 2002, 196, 85-90.
• Yang L., DeBusk L. M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L. M., Carbone D. P., Lin P. C.: Expansion of myeloid immune suppressor Gr1CD11b1 cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6, 409-421.
• Yang L., Huang J., Ren X., Gorska A. E., Chytil A., Aakre M., Carbone D. P., Matrisian L. M., Richmond A., Lin P. C., Moses H. L.: Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13, 23-35.
• Youn J. I., Nagaraj S., Collazo M., Gabrilovich D. I.: Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 2008, 181, 5791-5802.
• Zhang L., Jose R. Conejo-Garcia, Katsaros D., Phyllis A. Gimotty, Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M. N., Rubin S. R., Coukos G.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England J. Med. 2003, 348, 203-213.
• Zhao M., Gao F. H., Wang J. Y., Liu F., Yuan H. H., Zhang W. Y., Jing B.: JAK2/STAT3 signaling pathway activation mediated tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer 2011, doi: 10.10.16/j.lungcan.2011.01.002.

Identyfikatory

DOI

10.21521/mw.5604